RESUMO
Purpose: Shivering occurs frequently after caesarean delivery. The present study aimed to investigate the ED50 and ED95 of an intravenous (i.v.) bolus of dexmedetomidine for treating severe shivering after caesarean delivery under combined spinal-epidural anaesthesia. Patients and methods: Seventy-five parturients with severe shivering after caesarean delivery were randomized into one of the five groups to receive an i.v. bolus of 0.2 (Group D1), 0.25 (Group D2), 0.3 (Group D3), 0.35 (Group D4) or 0.4 (Group D5) µg/kg of dexmedetomidine. Effectiveness of shivering treatment was defined as a standardized shivering score decreasing to ≤1 within 10 min of dexmedetomidine injection. The ED50 and ED95 were determined by probit regression. Adverse effects were also compared among the groups. Results: The ED50 and ED95 of i.v. dexmedetomidine to treat severe shivering were 0.23 (95% CI, 0.16-0.26) µg/kg and 0.39 (95% CI, 0.34-0.52) µg/kg, respectively. No difference in the incidence of adverse effects was found between groups. Conclusion: An i.v. bolus of 0.39 µg/kg of dexmedetomidine will treat 95% of parturients experiencing severe shivering after caesarean delivery.
Assuntos
Anestesia Epidural , Raquianestesia , Cesárea , Dexmedetomidina , Relação Dose-Resposta a Droga , Estremecimento , Dexmedetomidina/administração & dosagem , Dexmedetomidina/efeitos adversos , Humanos , Estremecimento/efeitos dos fármacos , Feminino , Adulto , Anestesia Epidural/efeitos adversos , Gravidez , Injeções Intravenosas , Adulto JovemRESUMO
BACKGROUND: Propofol is commonly used for procedural sedation but may increase side effects in a dose-dependent manner. Remimazolam, an ultrashort-acting benzodiazepine, has been approved for procedural sedation but may delay awakening. This study tested the hypothesis that remimazolam as a supplement reduces effect-site propofol concentration (Ceprop) required to suppress response to cervical dilation in patients undergoing hysteroscopy. METHODS: One hundred and fifty patients who were scheduled for hysteroscopy were randomized to receive 0, 0.05, 0.1, 0.15, or 0.2 mg·kg-1 intravenous remimazolam, followed by a bolus of sufentanil 0.15 µgâ kg-1, and a target-controlled propofol infusion. The initial target Ceprop was 3.5 µg·mL-1 and was increased or decreased in subsequent patients by steps of 0.5 µg·mL-1 according to whether there was loss of response to cervical dilation in the previous patient. We used up-down sequential analysis to determine values of Ceprop that suppressed response to cervical dilation in 50% of patients (EC50). RESULTS: The EC50 of propofol for suppressing response to cervical dilation was lower in patients given 0.1 mg·kg-1 (2.08 [95% confidence interval, CI, 1.88-2.28] µg·mL-1), 0.15 mgâ kg-1 (1.83 [1.56-2.10] µg·mL-1), and 0.2 mgâ kg-1 (1.43 [1.27-1.58] µg·mL-1) remimazolam than those given 0 mgâ kg-1 (3.67 [3.49-3.86] µg·mL-1) or 0.05 mgâ kg-1 (3.47 [3.28-3.67] µg·mL-1) remimazolam (all were P < .005). Remimazolam at doses of 0.1, 0.15, and 0.2 mg·kg-1 decreased EC50 of propofol by 43.3% (95% CI, 41.3%-45.5%), 50.3% (48.0%-52.8%), and 61.2% (58.7%-63.8%), respectively, from baseline (remimazolam 0 mgâ kg-1). Propofol consumption was lower in patients given 0.1 mgâ kg-1 (4.15 [3.51-5.44] mg·kg-1), 0.15 mgâ kg-1 (3.54 [3.16-4.46] mg·kg-1), and 0.2 mgâ kg-1 (2.74 [1.73-4.01] mg·kg-1) remimazolam than those given 0 mgâ kg-1 (6.09 [4.99-7.35] mg·kg-1) remimazolam (all were P < .005). Time to anesthesia emergence did not differ significantly among the 5 groups. CONCLUSIONS: For women undergoing hysteroscopic procedures, remimazolam at doses from 0.1 to 0.2 mg·kg-1 reduced the EC50 of propofol inhibiting response to cervical dilation and the total propofol requirement. Whether the combination could improve perioperative outcomes deserves further investigation.